These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 22723290)

  • 1. The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension.
    Mathai SC; Puhan MA; Lam D; Wise RA
    Am J Respir Crit Care Med; 2012 Sep; 186(5):428-33. PubMed ID: 22723290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study.
    Oudiz RJ; Brundage BH; Galiè N; Ghofrani HA; Simonneau G; Botros FT; Chan M; Beardsworth A; Barst RJ;
    J Am Coll Cardiol; 2012 Aug; 60(8):768-74. PubMed ID: 22818063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex differences in response to tadalafil in pulmonary arterial hypertension.
    Mathai SC; Hassoun PM; Puhan MA; Zhou Y; Wise RA
    Chest; 2015 Jan; 147(1):188-197. PubMed ID: 25122150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.
    Kimura M; Tamura Y; Takei M; Yamamoto T; Ono T; Fujita J; Kataoka M; Kuwana M; Satoh T; Fukuda K
    BMC Pulm Med; 2015 May; 15():62. PubMed ID: 25971443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension.
    Udeoji DU; Schwarz ER
    Ther Adv Respir Dis; 2013 Feb; 7(1):39-49. PubMed ID: 23129569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tadalafil therapy and health-related quality of life in pulmonary arterial hypertension.
    Pepke-Zaba J; Beardsworth A; Chan M; Angalakuditi M
    Curr Med Res Opin; 2009 Oct; 25(10):2479-85. PubMed ID: 19686085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
    Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
    Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel therapeutic approaches in pulmonary arterial hypertension: focus on tadalafil.
    Levin YD; White RJ
    Drugs Today (Barc); 2011 Feb; 47(2):145-56. PubMed ID: 21431102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Minimal Important Difference in Borg Dyspnea Score in Pulmonary Arterial Hypertension.
    Khair RM; Nwaneri C; Damico RL; Kolb T; Hassoun PM; Mathai SC
    Ann Am Thorac Soc; 2016 Jun; 13(6):842-9. PubMed ID: 26974862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion from sildenafil to tadalafil: results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study.
    Frantz RP; Durst L; Burger CD; Oudiz RJ; Bourge RC; Franco V; Waxman AB; McDevitt S; Walker S
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):550-7. PubMed ID: 24742768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension.
    Arif SA; Poon H
    Clin Ther; 2011 Aug; 33(8):993-1004. PubMed ID: 21762988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pulmonary hypertension gas exchange severity (PH-GXS) score to assist with the assessment and monitoring of pulmonary arterial hypertension.
    Woods PR; Taylor BJ; Frantz RP; Johnson BD
    Am J Cardiol; 2012 Apr; 109(7):1066-72. PubMed ID: 22245407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors.
    Channick R; Preston I; Klinger JR
    Clin Chest Med; 2013 Dec; 34(4):811-24. PubMed ID: 24267306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials.
    Liu HL; Chen XY; Li JR; Su SW; Ding T; Shi CX; Jiang YF; Zhu ZN
    Chest; 2016 Aug; 150(2):353-66. PubMed ID: 27048870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
    Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ;
    Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial.
    Goudie AR; Lipworth BJ; Hopkinson PJ; Wei L; Struthers AD
    Lancet Respir Med; 2014 Apr; 2(4):293-300. PubMed ID: 24717626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension.
    Shapiro S; Traiger G; Hill W; Zhang L; Doran AK
    Cardiovasc Ther; 2013 Oct; 31(5):274-9. PubMed ID: 23841794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal Clinically Important Difference in the 6-minute-walk Distance for Patients with Pulmonary Arterial Hypertension.
    Moutchia J; McClelland RL; Al-Naamani N; Appleby DH; Blank K; Grinnan D; Holmes JH; Mathai SC; Minhas J; Ventetuolo CE; Zamanian RT; Kawut SM
    Am J Respir Crit Care Med; 2023 Apr; 207(8):1070-1079. PubMed ID: 36629737
    [No Abstract]   [Full Text] [Related]  

  • 19. Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension.
    Zhuang Y; Jiang B; Gao H; Zhao W
    Hypertens Res; 2014 Jun; 37(6):507-12. PubMed ID: 24646647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1).
    Shapiro S; Torres F; Feldman J; Keogh A; Allard M; Blair C; Gillies H; Tislow J; Oudiz RJ
    Respir Med; 2017 May; 126():84-92. PubMed ID: 28427554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.